An update on the use and investigation of probiotics in health and disease. by Sanders, Mary Ellen et al.
UCLA
UCLA Previously Published Works
Title
An update on the use and investigation of probiotics in health and disease.
Permalink
https://escholarship.org/uc/item/3g69w1fb
Journal
Gut, 62(5)
ISSN
0017-5749
Authors
Sanders, Mary Ellen
Guarner, Francisco
Guerrant, Richard
et al.
Publication Date
2013-05-01
DOI
10.1136/gutjnl-2012-302504
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
An update on the use and investigation of probiotics in health 
and disease
Mary Ellen Sanders1, Francisco Guarner2, Richard Guerrant3, Peter R Holt4, Eamonn MM 
Quigley5,6, R Balfour Sartor7, Philip M Sherman8, and Emeran A Mayer9
1Dairy & Food Culture Technologies, Centennial, Colorado, USA 2Digestive System Research 
Unit, University Hospital Vall d’Hebron, CIBEREHD, Barcelona, Spain 3Center for Global Health, 
University of Virginia School of Medicine, Charlottesville, Virginia, USA 4Laboratory of 
Biochemical Genetics & Metabolism, The Rockefeller University, New York City, New York, USA 
5Department of Medicine, Alimentary Pharmabiotic Centre, University College Cork, Ireland 
6Division of Gastroenterology and Hepatology, The Methodist Hospital and Weill Cornell School 
of Medicine, Houston, Texas, USA 7Departments of Medicine, Microbiology and Immunology, 
University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA 
8The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada 9Division of 
Digestive Diseases, University of California, Los Angeles, California, USA
Abstract
Probiotics are derived from traditional fermented foods, from beneficial commensals or from the 
environment. They act through diverse mechanisms affecting the composition or function of the 
commensal microbiota and by altering host epithelial and immunological responses. Certain 
probiotic interventions have shown promise in selected clinical conditions where aberrant 
microbiota have been reported, such as atopic dermatitis, necrotising enterocolitis, pouchitis and 
possibly irritable bowel syndrome. However, no studies have been conducted that can causally 
link clinical improvements to probiotic-induced microbiota changes. Whether a disease-prone 
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microbiota pattern can be remodelled to a more robust, resilient and disease-free state by probiotic 
administration remains a key unanswered question. Progress in this area will be facilitated by: 
optimising strain, dose and product formulations, including protective commensal species; 
matching these formulations with selectively responsive subpopulations; and identifying ways to 
manipulate diet to modify bacterial profiles and metabolism.
INTRODUCTION
‘If gut bacteria are making you ill, can swapping them make you healthy?’ asks an article 
from The Economist (18 August 2012, ‘Me, myself, us’, p69). This is where the concept of 
probiotics enters the discussion about microbiota gone awry. Probiotics are live micro-
organisms, which, when administered in adequate amounts, confer a health benefit to the 
host. Probiotics act through diverse mechanisms that affect the microbiota.12 This effect 
may be revealed through changes in either the populations of bacteria or bacterial metabolic 
activity. A recent study demonstrated that a probiotic yogurt changed urinary bacterial 
metabolites, but not faecal bacterial community populations.3 Such results suggest that 
probiotics may have the potential to affect the function more than the structure of the 
microbiome. Probiotics are the subject of increasing basic and clinical research, while also 
being incorporated into an expanding array of foods, nutritional supplements and 
pharmaceutical products globally (figure 1).
The literature on the health benefits of probiotics has often focused on disease states using 
either animal models of such diseases or studies in human populations.4 More recently, 
investigators have been asking how to measure the impact of probiotics on healthy 
individuals, such as reducing the risk of developing disease or optimising physiological 
function within normal ranges. The distinction between research aimed at maintaining health 
and that aimed at treating a disease has important regulatory implications; the former can be 
applied to foods and supplements, whereas the latter is confined to drugs.
This review provides an update on probiotic effects on treatment or prevention of important 
gastroenterological conditions: irritable bowel syndrome (IBS), infectious diarrhoea 
including nosocomial infections, inflammatory bowel disease (IBD), necrotising 
enterocolitis (NEC), as well as cancer and cancer therapy. We also address the impact of 
probiotics on indicators of health, as measured through reduction in the incidence of 
common infectious diseases and risk of allergy, improvement in bowel function, and 
modulation of immune function. When available, conclusions arising from meta-analyses or 
systematic reviews on probiotic effects are provided. Lastly, we highlight challenges and 
opportunities in conducting human research in this field.
PROBIOTICS IN HEALTH AND DISEASE
Irritable bowel syndrome
IBS is one of the most common intestinal disorders in industrialised (affecting 10–15% of 
the population) and developing countries and incurs significant healthcare costs.56 In the 
absence of generally agreed upon biomarkers, IBS is currently defined by symptom criteria, 
which include chronic recurring episodes of abdominal pain or discomfort associated with 
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altered bowel habits in the absence of organic disease.7 In addition, sensations of bloating 
with and without visible abdominal distension, increased trait anxiety and several 
extraintestinal symptoms commonly occur.578 Since IBS-like symptoms can also occur in a 
milder form in healthy individuals, studies on subjects with IBS are relevant to the general, 
undiagnosed population, as reflected in the European regulatory framework.9 Although 
preliminary evidence suggests alterations in gut microbiota in patients with IBS,10–15 it 
remains to be determined if these alterations are a cause or a consequence of altered gut 
motility and secretion.16 Recent preclinical data support the concept that gut microbiota and 
probiotics affect enteric nervous system and brain signalling; beneficial effects of probiotics 
on visceral nociceptive reflexes in rodents have also been described.17 However, only 
preliminary data suggest that such mechanisms may also play a role in healthy subjects or 
those with IBS.18
A growing number of meta-analyses vary in their conclusions on the effectiveness of 
probiotics against IBS, in part because of inadequate sample size, poor study design and use 
of various probiotic strains in the reviewed studies.19–21 Moayyedi et al19 reviewed 19 
randomised, controlled trials (RCTs) performed in 1650 patients with IBS and concluded 
that probiotics were better than placebo (relative risk of IBS not improving 0.71 (95% CI 
0.57 to 0.88) with a number needed to treat of 4 (95% CI 3.0 to 12.5)). Clarke et al20 
reviewed 42 RCTs of the effect of lactic acid bacteria probiotics on IBS symptoms. Thirty-
four of these trials reported benefit in at least one of the end points studied. Brenner et al21 
evaluated 16 strictly selected RCTs and found 11 that were inadequately blinded, of too 
short duration, of too small sample size, and/or lacked intention to treat analysis. They 
concluded that only two of the studies—those using Bifidobacterium infantis 356242223—
showed significant improvements in abdominal pain/discomfort, bloating/distension and/or 
bowel movements compared with placebo. Given the controversies in IBS pathophysiology, 
patient heterogeneity, or lack of clear, reproducible evidence for gut microbiota 
abnormalities in patients with IBS, additional RCTs with appropriate end points and design 
are needed to determine the extent to which (and in which IBS subpopulations) certain 
probiotics are useful therapeutic strategies in the management of IBS symptoms.
Infectious diarrhoea
Enteric and diarrhoeal diseases are leading causes of morbidity and mortality among 
children under the age of 5 worldwide, with low- and middle-income countries bearing the 
brunt of this burden.24 Repeated infections lead to acute and chronic undernutrition, 
resulting in more frequent and more severe infections; eventually this leads to 
developmental deficits in growth, fitness and cognition, which persist into adulthood with 
devastating human and economic consequences globally.25–27 A better understanding of the 
intestinal microbiota and of potential action mechanisms of probiotics has led to studies 
evaluating their efficacy in acute infectious gastroenteritis28 and in the setting of persistent 
diarrhoea.29 Such approaches have the potential to help reduce the global burden of 
childhood disease.30 Treatment of acute diarrhoea with probiotics appears to reduce 
diarrhoea duration by about 1 day (predominantly in developed areas; 22 studies carried out 
in developing areas were more variable).252831 In persistent diarrhoea in developing areas, 
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an approximate 4-day reduction in the duration of persistent diarrhoea, coupled with 
improved growth parameters, has been noted.252931
Several studies with probiotics, including Saccharomyces boulardi, Lactobacillus 
rhamnosus GG and other strains report reductions in nosocomial diarrhoea rates, as well as 
reductions in antibiotic-associated diarrhoea and recurrences of Clostridium difficile-
associated diarrhoea.3132 These effects include a 40–60% reduction in the frequency of 
antibiotic-associated diarrhoea, but studies documenting a reduction in C difficile-associated 
diarrhoea are far fewer and remain the subject of controversy.33–36 Indeed, Floch et al32 
considered evidence insufficient for an ‘A’ recommendation for this indication.
Nosocomial infections remain a major healthcare concern, with estimated yearly direct 
medical costs in the USA of US $28–45 billion,37 pointing to the need for a preventive 
approach. However, the results of studies evaluating the preventive effect of probiotics on 
nosocomial infections have been mixed. Some show benefit,3839 whereas others do not.40–42 
Three RCTs (including 1043 children) tested L rhamnosus GG supplementation and showed 
significantly reduced rates of nosocomial rotavirus diarrhoea.3942–44 Supplementing infant 
formula with B bifidum and Streptococcus thermophilus reduced the frequency of episodes 
of acute infectious diarrhoea.45 L rhamnosus GG was effective in reducing nosocomial 
gastrointestinal and respiratory tract illnesses in over 2000 immunocompetent children ≥1 
year of age without underlying illnesses who were suddenly hospitalised for reasons 
unrelated to gastrointestinal or respiratory tract problems.39 Although probiotics show 
promise in reducing nosocomial infections among some populations, they are not 
recommended for critically ill hospitalised patients at this time.4647
Inflammatory bowel disease
Probiotic treatments of IBD have yet to meet the high expectations predicted by mechanistic 
and animal studies, especially for Crohn’s disease.4849 No consistent effects have been 
noted in treating or preventing relapse of Crohn’s disease. For ulcerative colitis, benefits 
have been described for a combination of Lactobacillus, Bifidobacterium and Streptococcus 
probiotic species or for Escherichia coli Nissle in inducing and maintaining remission of 
disease activity in mild to moderately severe ulcerative colitis.50–53 Primary prevention of 
pouchitis and reducing the likelihood of relapse after successful antibiotic treatment has also 
been successful, receiving an ‘A’ recommendation by Floch et al.32
Possible reasons for the current disparity between therapeutic potential and actual clinical 
outcomes of probiotic use in IBD are summarised in table 1, which includes proposed 
strategies to enhance therapeutic outcomes. Although created for IBD, this conceptual 
framework is relevant to other complex disorders such as IBS, colorectal and gastric 
cancers, non-alcoholic steatohepatitis and autoimmune diseases. In these diseases, 
interactions between genetic, microbial and environmental influences lead to heterogeneous 
phenotypes in patient subsets that are uniquely responsive to specific microbial 
manipulations. Functions associated with the over 160 genetic polymorphisms associated 
with IBD can be broadly grouped as defective mucosal barrier function/healing, abnormal 
immunoregulation and defective microbial recognition/killing. Immunosuppression in a 
patient with defective bacterial killing may be counterproductive. Likewise an individual 
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with dysbiosis may respond better to selective restoration of protective commensal species, 
such as Faecalibacterium prausnitzii or Clostridium species, than to exogenous agents such 
as traditional probiotics. Polymorphisms in IBD-related genes that regulate mucus 
glycosylation, such as Fut2, which encodes α1,2-fucosyltransferase and is associated with 
abnormal bacterial profiles, may selectively improve response to alternative bacterial 
nutritional sources, such as prebiotics.54
The extraction or synthesis of molecules derived from probiotic or protective enteric species 
could also prove useful. For example, immunoactive purified products such as p40 from L 
rhamnosus GG or polysaccharide A from Bacteroides fragilis with defined biological 
actions could be synthesised and administered.5556 In addition, bacteria can be engineered to 
produce interleukin 10, trefoil factors or elafin.57 An alternative approach is to identify and 
develop dietary strategies to selectively enhance the growth and function of endogenous 
commensals or diminish the activities of detrimental bacteria. For example, prebiotics such 
as inulin or fructose oligosaccharides increase luminal numbers of Bifidobacterium species 
and concentrations of protective short-chain fatty acids, which are important metabolic 
substrates for colonic epithelial cells. In contrast, refined sugars and food additives, such as 
iron, can increase proliferation of detrimental bacterial species, including E coli, Klebsiella 
pneumonia and Enterococcus faecalis.5859 These dietary substances could be avoided to 
provide better maintenance of healthy states.
One potential therapeutic approach to management of IBD might be to induce rapid clinical 
remission and mucosal healing with corticosteroid and/or biological therapy followed by 
probiotic and/or prebiotic interventions to sustain remission (table 2). This novel treatment 
paradigm remains unproven, but is designed to stimulate new directions of clinical and 
translational research that have the potential to improve therapeutic results while decreasing 
long-term toxicity and costs.
Necrotising enterocolitis
Differences in intestinal microbiota of preterm versus term infants may factor into the 
preterm infants’ predisposition to NEC.60 The microbiota of infants with NEC differ from 
that of other low-birth-weight infants,61 particularly in decreased Firmicutes and increased 
gamma proteobacteria.62 Deep sequencing studies before the development of the disease 
suggest that individual operational taxonomic units differ between patients with NEC and 
controls.63 One line of evidence that altered microbiota may predispose infants to the 
development of NEC is the high prevalence of antibiotic usage in these premature infants.
At the present time, NEC is associated with 30% mortality, despite extensive medical and 
surgical efforts, and with severe and costly sequelae if the patient survives. The disease can 
be difficult to diagnose before intestinal perforation occurs. The immature intestine of 
preterm infants is especially prone to inflammation and loss of epithelial integrity.64 Since 
probiotics have potential to interfere with this progression, they have been tested clinically 
for NEC. Indeed, meta-analyses of probiotic studies using strains of Bifidobacterium, 
Lactobacillus, Saccharomyces and/or S thermophilus to prevent NEC show reduction in the 
frequency and reduction in overall mortality.65 A study from Egypt reported that L 
rhamnosus GG, or a killed preparation of the same probiotic strain, significantly reduced the 
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incidence of NEC.66 Although the American Academy of Pediatrics recognises that there is 
evidence that probiotics prevent NEC in very-low-birth-weight infants, they call for more 
studies to clarify the effective dose and strain of probiotic before issuing clinical 
recommendations.67 For example, one systematic review of three RCTs evaluating 
Bifidobacterium animalis CNCM I-3446 in 293 preterm babies reported only a trend 
towards prevention of NEC, suggesting that this treatment regimen may not be as effective 
as others.68 Others consider available evidence sufficient to support a change in practice.69 
This opinion is based on the lack of treatment options for NEC and the strength of evidence 
that probiotics can prevent severe NEC and all-cause mortality in preterm infants.
Cancer and cancer therapies
Colorectal cancer (CRC) is one of the most common cancers worldwide. Several molecular 
and cellular steps in the carcinogenic pathways have been defined, and the body of evidence 
indicates a prominent causative role for environmental factors, including obesity and diet. 
Both of these factors are associated with changes in the gut microbiome. It is noteworthy 
that tumour incidence and mass are greater in conventional than in germ-free rodents.70 
Taken together, these findings strongly support the concept that the microbiota play some 
role in CRC, but causality remains to be confirmed. Sears et al71 have presented evidence 
that enterotoxigenic B fragilis, for example, may trigger E cadherin catabolism, provoke 
intestinal inflammation, and thereby increase the risk of colonic cancer. Others have 
analysed the microbiology in patients with CRC and suggested that the bacterial diversity is 
less,72 altered7374 or accompanied by high levels of Fusobacterium nucleatum sequences.75 
Studies in rodents have concentrated on probiotic effects on precancerous lesions and 
tumours. Such studies have yielded consistent, beneficial effects.7677 Several potential 
mechanisms have been described, including alterations in microbiota species and 
metabolism, changes in colonic pH, binding or inactivation of carcinogens, enhanced 
immune responses, reduced colonic inflammation, lowered epithelial proliferation and 
increased apoptosis.78
Biomarker studies in humans show that synbiotics reduced faecal-water-induced genotoxic 
damage and increased transepithelial resistance.7980 A synbiotic combination of an 
oligofructose-enriched inulin preparation combined with two probiotics did not affect 
epithelial cell proliferation81 but reduced evidence of faecal-water-induced DNA damage in 
HT29 and colonic epithelial cells.82 Rowland and colleagues focused on how administering 
a prebiotic–probiotic mixture could affect faecal-water genotoxicity in cell culture studies, 
and demonstrated pronounced within-individual changes in barrier function, immune cell 
activity, immune cell proliferation and apoptosis. One consistent observation is that a 
synbiotic preparation appears to be more effective in altering biomarkers of CRC risk than a 
single probiotic or prebiotic. One human study showed a reduced rate of recurrence of 
adenoma atypia after 4 years of Lactobacillus casei administration.83 Finally, a 12-year 
follow-up of over 45 000 volunteers with a high intake of yogurt in an Italian cohort 
reported a reduction in CRC, although there was no comparator group in this study.84 
Although the few human studies conducted on cancer end points in humans are encouraging, 
the end points are diverse, and findings need to be expanded before clinical 
recommendations can be considered.
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Radiotherapy and chemotherapy, widely used either alone or in combination for the 
management of intra-abdominal and intrapelvic cancers, kill replicating cells in the rapidly 
proliferating normal small and large intestine. Probiotics have been evaluated to help 
manage side effects of these therapies. Germ-free mice and animals in which the microbiota 
have been modified by antibiotics are more resistant to radiation toxicity, providing a basis 
for suspecting that interventions targeting the micro-biota may be effective.8586 L 
rhamnosus GG and its conditioned medium were found to reduce intestinal damage and 
apoptosis from radiation in the proximal jejunum of mice in a TLR2-, COX2- and MyD88-
dependent fashion.5587 L rhamnosus GG protection appears to be mediated through the 
unusual mechanism of increased migration of mesenchymal stem cells into the lamina 
propria. Others also describe the beneficial effects of different probiotics given to patients 
receiving chemotherapy8889 or radiation.90 These and other studies point to the potential 
beneficial effect of probiotics in the amelioration of radiation and chemotherapy damage to 
the small bowel and large intestine of patients being treated for cancers. Incapacitating 
diarrhoea, dehydration and malnutrition are adverse effects of radiotherapy and 
chemotherapy, which can limit the amounts of therapy that can be administered, thus 
compromising patient management.91 Probiotics that effectively mitigate these side effects 
of cancer treatment could be important therapeutic agents.
Allergy
Allergic disorders have been associated with aberrant gut micro-biota.92 Factors associated 
with allergy such as birth delivery mode (caesarean section vs vaginal delivery),93 antibiotic 
use in the newborn and infant, and non-breast-milk diets are also associated with shifts in 
the gut microbiota. In the last several decades, an increasing number of children 
(approximately 10% of the general population) develop allergy in a clinical progression of 
the so-called ‘atopic march’ (eczema → rhinitis → asthma). Probiotics have been studied as 
possible dietary interventions to interrupt this disease progression. A much higher incidence 
of atopy is described among infants born into a family with an allergic history. For people 
with such a family history, strategies using probiotics for prevention should begin early, 
since most studies designed to assess prevention of atopic dermatitis with probiotics have 
been conducted in the last stages of pregnancy and during lactation. Several studies have 
shown a persistent and significantly reduced rate of atopic dermatitis for up to 7 years.9495 
However, no effect on the expression of asthma later in childhood has been observed. An 
ideal study would follow allergy-prone compared with non-allergy-prone infants from late 
pregnancy until late childhood and test for the expression of all forms of allergy, as well as 
sensitivity, using a standardised protocol.9697 As the situation now stands, evidence of 
efficacy is not convincing enough to compel paediatric organisations to recommend routine 
use of probiotics.
Common infectious diseases
The gut microbiota are being recognised for their role in promoting resistance to non-enteric 
pathogens, possibly through enhanced barrier function, production of anti-pathogenic 
substances and improved immune function.98 Research reviewed by Borchers et al99 
suggests that certain probiotics can regulate critical components of the immune system, such 
as lymphocytes, antibodies and natural killer cells. As an extension of these functions, the 
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potential of probiotics to reduce common infectious diseases has been studied.100101 A 
meta-analysis conducted on the effectiveness of probiotics in preventing acute upper 
respiratory tract infections (URTIs)100 analysed 10 trials involving 3451 participants and 
found that probiotics reduced the number of participants experiencing acute URTI. Other 
studies, including two large cohort studies, found that probiotics reduced the duration and 
severity of influenza-like symptoms in children.102103 A community-based study in the USA 
showed that ingestion of probiotic-containing milk reduced the frequency of acute diarrhoeal 
illnesses by 24% and URTI by 18%, but with no difference in rates of lower respiratory tract 
infections.101 A community-based study of children living in impoverished conditions in 
India tested milk fortified with L casei Shirota compared with a nutrient drink in 3758 1–5-
year-old children.104 The frequency of acute diarrhoeal episodes was reduced by 14% in the 
probiotic group. Another study reported that a probiotic significantly shortened the duration 
of individual episodes of URTI (by almost 2 days) and reduced the severity of URTI 
symptoms even though the product had no effect on the frequency.105 Taken together, these 
studies suggest that probiotics in otherwise healthy individuals may reduce common 
infectious diseases.
For most of the conditions discussed, there is evidence suggesting benefit of probiotics. 
However, before definitive treatment or dietary management recommendations can be made, 
a systematic approach to evaluating the strength of evidence is needed to identify limitations 
in existing clinical studies. A clear definition of effective probiotic strain(s) and doses, 
identification of responding populations, quantification of the magnitude of expected effects, 
and characterisation of underlying microbiota deficiencies (microbes and/or their 
metabolites) are important for full implementation of probiotic interventions.
CHALLENGES TO STUDYING HEALTH EFFECTS OF PROBIOTICS
The findings from research reach their full potential when translated into effective products. 
Part of this process requires understanding the regulatory issues leading to technology 
transfer and commercialisation. This section addresses how to design human trials to be both 
scientifically meaningful and appropriate for corresponding product category regulations. 
Those designing clinical trials need to be mindful of recent regulatory actions pertinent to 
the probiotic field and of the potential challenges imposed by regulatory frameworks, 
especially in the USA and Europe.
Designing a clinical study on probiotics
The value of well-controlled and well-designed human trials to elucidate probiotic efficacy 
is self-evident. However, the current heightened scrutiny from regulatory authorities on 
health benefit claims made on packaging and in advertising, combined with strict 
interpretations regarding what constitutes drug research, requires carefully weighing 
regulatory issues when designing and launching probiotic studies for food or supplement 
uses. Many issues worth addressing in the planning stages by both researchers and study 
sponsors are described in box 1.
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Box 1
Questions to consider before designing, conducting and reporting human 
studies on probiotics
• Will the study be performed among healthy subjects or in a disease population? 
Foods and dietary supplements are products generally intended for the healthy 
population. Therefore, trials designed to support claims about this category of 
products should be conducted on subjects who are representative of the healthy 
general population. If the target is a disease state, then the study must be 
performed in an appropriately selected study population representative of that 
disorder, and the study should conform to the standards of a pharmaceutical 
product.
• What is the regulatory approach to health benefit claims in your jurisdiction on 
the type of product you intend to market? Will the product be a food, 
supplement, drug or other? Efficacy standards, appropriate study end points, 
target populations and risk assessment all vary for the different categories of 
product, and the clinical research programme needs to reflect these differences.
• If seeking support for a claim for a probiotic food or supplement, what precisely 
is the claim and will it be supported by the study that you propose? The primary 
end point in the research study should be as close as possible to the benefit that 
will be communicated. Outcomes must be clear and measurable, and the study 
protocol should preferably involve a randomised, double-blind, placebo-
controlled design. The selected placebo must be very similar to the probiotic 
food in terms of nutritional profile, taste, texture, colour and flavour, but should 
be devoid of the probiotic strains.
• Has the strain(s) of choice been adequately characterised, in terms of its 
genome, in vitro properties and in vivo activities, and ability to survive transit 
through the gastrointestinal tract? Thorough strain characterisation is critical to a 
full understanding of the substance being studied, and also to ensure the ease of 
repetition of the study by other research groups.
• Has the proposed formulation been shown to retain viability and efficacy for the 
duration of its proposed shelf life and in the environment in which it is likely to 
be marketed?
• Has a plausible rationale been developed for the use of this/ these particular 
strain/strains in this indication? Although a confirmed mechanism of action is 
not considered essential for functional food ingredients (or drugs, for that 
matter), a plausible rationale is preferred.
• Has the optimal target population been clearly defined for this particular 
probiotic and the specific outcome you plan to modify? If the target population 
is some subset of the general population for a food or supplement, it is important 
to document this.
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• What dose will be tested? Is there any indication of an effective dose from 
previous studies? The dose used in the study must be high enough to confer the 
benefit, but not so high as to make the product commercially untenable. Since 
the product dose must match the dose in the human trial showing benefit, dose 
used in the study is an important consideration.
One fundamental issue in the concept of probiotics that is often not addressed in clinical 
trials is the importance of probiotic viability to the physiological benefit; non-viable controls 
are rarely used in studies. Although many of the mechanisms proposed for probiotic activity 
probably require growth and metabolism at the physiological site of action, confirmation of 
the requirement for viability through design of clinical studies with a non-viable control 
would clarify this issue. However, a non-viable product is not considered to be a probiotic, 
which by definition must be a live microbe. Such a product would fall under the more 
general term, ‘pharmabiotic’, which encompasses non-viable microbes and health-
promoting substances derived from micro-organisms.48
Effect of regulatory frameworks on probiotic development pathways
The approach to marketing probiotic products is inextricably tied to the regulatory 
framework. These frameworks, although different in different countries worldwide, affect 
research approaches, communication strategies, product manufacturing and product labels. 
The importance of these regulatory matters in current times is reflected in some recent 
papers.106–109
A research path must stand up to scientific scrutiny, but also must comply with regulatory 
definitions of what constitutes appropriate research end points for specific product 
categories. The path for research on drugs is fairly clear. However, the path to provide 
evidence that will substantiate a health benefit claim for a food or dietary supplement is not 
as obvious. Many probiotic products are marketed as foods or dietary supplements, yet much 
of the research documenting health benefits is considered by regulatory authorities of some 
countries to be drug-use end points. Such research may not be considered appropriate to 
substantiate health benefits of food, as foods are not regulated as disease prevention or 
treatment measures, but only to support or maintain normal body functions or reduce the risk 
of disease in the general population. (The claim that a ‘food’ can treat or prevent disease 
turns it into a drug.) One challenge therefore is how to conduct meaningful studies to show 
that health is improved—or, even more challenging, maintained—in a healthy person? What 
does ‘maintained’ mean with respect to a study’s primary outcome?
Communicating health benefits on probiotic products has emerged as a challenge for 
probiotic companies. For example, in Europe, no health benefit claims for a probiotic have 
been approved, apparently because the level of evidence does not meet the expectations of 
the regulatory authorities. Further, claims of disease risk reduction require demonstrated 
changes in commonly accepted risk factors for specific diseases. Changes in a clinical end 
point are not sufficient, and many of the diseases/disorders for which probiotics are being 
explored lack validated biomarkers. In the USA, claims worded as ‘structure/function’ 
claims (eg, ‘this probiotic improves digestive health’) do not require approval, but must be 
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substantiated nonetheless. Here the challenge is what types of studies support such a general 
claim.
Despite the lack of clarity in how to substantiate claims, regulatory authorities in the USA 
have increased their scrutiny of structure/function claims, demanding that the claims meet 
regulatory standards for substantiation. A growing body of scientific evidence demonstrates 
that some probiotic foods or supplements may prevent or mitigate some diseases or 
illnesses. These products may be foods or supplements in the mind of consumers, but are 
considered drugs by regulators.
THE FUTURE
An association of microbiome alterations with a progression from health to disease seems 
clear. However, causality and reversal of disease in response to probiotic-induced 
microbiome changes still remain to be demonstrated.110111 Until a healthy microbiome is 
clearly defined, providing a microbiological target for probiotic interventions, probiotic 
benefits must be described in the context of physiological or clinical improvement. Some 
promising immune and gastrointestinal clinical targets have been identified in this review, 
including paediatric rotavirus diarrhoea, antibiotic-associated diarrhoea, C difficile-
associated diarrhoea, ulcerative colitis, pouchitis, IBS, NEC and radiation enteritis. Beyond 
these, probiotic interventions with implications outside the gastrointestinal tract are 
increasingly recognised. Perhaps the most intriguing targets are focused on microbiota-
influenced conditions of diabetes, the metabolic syndrome and obesity, where studies in 
animal models indicate functional involvement of the microbiota. To what extent targeted 
probiotic interventions affect these diseases is an area of active and evolving research.
In the future, probiotics developed to address microbiota-associated conditions will probably 
move beyond the micro-organisms commonly used as probiotics today. Genetically 
modified micro-organisms can provide epitopes for efficient oral vaccine delivery, improve 
vaccine or natural immune responses, or restore antigen-specific tolerance.112113 Probiotic 
strains with altered cell surface components, such as lipoteichoic acid, provide a potential 
strategy for the treatment of inflammatory intestinal disorders.57114 The use of faecal 
transplants to replace dysbiotic bacterial communities with protective ones in order to 
manage C difficile infections, IBD or IBS has met with some success.115 Recently, faecal 
microbiota transplant from non-diabetic donors infused into the duodenum of patients with 
the metabolic syndrome improved their insulin sensitivity, highlighting the broad potential 
of this intervention.116 However, cocktails of defined microbes imparting key functionalities 
may provide a more acceptable approach. Finally, specific strains with uniquely useful 
properties, such as Oxalobacter formigines (kidney stones), F prausnitzii (chronic gut 
inflammation), Bacteroidetes and Fusobacterium (cancer risk), should be more thoroughly 
studied in well-designed clinical trials.
Probiotic interventions for extending the remission of IBD show promise for pouchitis and 
ulcerative colitis, but success with Crohn’s disease will require new approaches. 
Identification of specific protective molecules, such as interleukin 10, ganglioside and trefoil 
factors, that can be engineered into probiotics for in situ release holds promise.112117 More 
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effective probiotic interventions for microbiota-associated conditions require a more 
complete understanding of the interactions between genetic, microbial and environmental 
influences within individuals. Such an approach will also facilitate the identification of 
subsets of patients most likely to respond to manipulations of the gut microbiota and the 
optimal agents to use in an individual subject.
Reducing the risk of disease with probiotics is promising, but validated biomarkers for many 
target diseases (such as allergy, infectious diarrhoea and IBS) are lacking. Consensus from 
the relevant research communities to define validated biomarkers would greatly advance this 
field. Measurement of meaningful physiological changes in healthy populations requires 
better definition as well. Identifying subjects on the edges of a normal physiological range, 
and intervening so as to move them closer to the median, may be a productive approach to 
research on healthy subjects. The effect of widespread use of safe and effective probiotic 
products on society-wide economic and quality-of-life indicators should be assessed with 
end points such as reduction of common infectious diseases in developing and developed 
nations. Such information could provide support for sustained research in this field.
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Key messages
Clinical uses of probiotics
• While altered microbiota have been associated with obesity, the metabolic 
syndrome, non-alcoholic steatohepatitis, inflammatory bowel disease, irritable 
bowel syndrome (IBS), atherosclerosis, type 1 diabetes, autism, allergy, asthma 
and coeliac disease, a cause-and-effect relationship in the pathogenesis of these 
disorders in relation to the role of mutualistic micro-organisms remains to be 
defined.
• A key unanswered question is whether disease-prone micro-biota can be 
remodelled to be more robust, resilient and disease-free with the use of 
probiotics as either a prevention or intervention strategy.
• Some probiotics can improve clinical outcomes for acute infectious diarrhoea, 
antibiotic-associated diarrhoea, necrotising enterocolitis, IBS, cancer therapies, 
pouchitis and possibly ulcerative colitis.
• Some probiotics deliver benefits for healthy individuals, such as reducing the 
risk of common infectious diseases and improving intestinal function.
• Probiotics probably function by altering the composition and/ or activities of the 
colonising microbiota and by direct interaction with the host through immune 
signalling mechanisms.
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Figure 1. 
Scope of probiotic products and uses. (A) Probiotics can be found in food, dietary/nutritional 
supplements, drugs and medical foods. Each product has country-specific legal requirements 
for allowed claims of efficacy, target populations, safety and risk/benefit assessment. (B) 
Hypothesised future uses for probiotics in modifying the composition or activities of the 
microbiota for improved health. (C) A range of health and clinical targets for different 
probiotics have been studied, encompassing intestinal and extraintestinal sites, and over a 
range of life stages. The evidence is strongest in the conditions shown in bold. Mechanisms 
for observed health effects may not be known, but probably include direct or indirect action 
on the activities and/or populations of gut microbiota and on the intestinal immune system. 
AAD, antibiotic-associated diarrhoea; CID, common infectious disease; IBS, irritable bowel 
syndrome; NEC, necrotising enterocolitis; RR, reduced risk; T, treatment; URTI, upper 
respiratory tract infections.
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Table 1
Possible explanations and proposed solutions for disappointing therapeutic results of probiotic treatment of 
IBD and other conditions
Reason for failure Proposed solution
Wrong targets Individualise treatment based on molecular pattern of dysbiosis
Wrong probiotic agents Use protective commensal enteric species, which may be more suitable than probiotics 
derived from cultured milk or foods, complex groups of commensal species or even 
intact normal bacterial communities (faecal transplant)
Targeting incorrect disease mechanisms Tailor therapeutic agent to correct underlying genetic defect/inflammatory pathway in 
an individual
Product not as potent as needed Genetically enhance bacterial function through addition or deletion of bioactive genes 
(pharmabiotics)
Product not administered at a time in relation to the 
disease onset where it can be effective
Target therapy to phase of disease process
Age of the subject Tailor therapy to age/developmental stage of individual subject
IBD, inflammatory bowel disease.
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Table 2
Future microbial and dietary interventions that could have a role in managing IBD and other intestinal 
inflammatory conditions once clinical remission and mucosal healing is established
Intervention and rationale Reference
Induce regulatory (protective) immune responses by probiotics, components of commensals such as Clostridium groups IV and 
XIVA, bacterial products such as polysaccharide A or dietary retinoic acid. Regulatory T cells maintain mucosal homoeostasis 
and can prevent relapse of inflammation.
56, 118
Improving mucosal barrier function with probiotics or their products, including p40 from Lactobacillus rhamnosus GG, and short-
chain fatty acids produced by Bifidobacterium and Clostridium species, including Faecalibacterium prausnitzii. Short-chain fatty 
acids such as butyrate that are products of bacterial metabolism of non-absorbed carbohydrates (fibre and prebiotics) are the 
primary metabolic fuel of colonic epithelial cells. Inflammation develops in the absence of short-chain fatty acids because of 
epithelial starvation/damage.
55
Decreasing luminal concentrations of antigens and TLR ligands that drive aggressive immune responses. Commensal luminal 
microbial antigens stimulate the TH1/TH17 responses that mediate chronic inflammation in Crohn’s disease.
49, 119
IBD, inflammatory bowel disease.
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